Alkermes PLC (ALKS)

49.74
0.06 0.12
NASDAQ : Health Care
Prev Close 49.80
Open 49.87
Day Low/High 49.28 / 49.97
52 Wk Low/High 27.14 / 80.71
Volume 67.44K
Avg Volume 1.01M
Exchange NASDAQ
Shares Outstanding 151.17M
Market Cap 7.40B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes Appoints Nancy Snyderman, M.D., To Board Of Directors

Alkermes Appoints Nancy Snyderman, M.D., To Board Of Directors

Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L.

Alkermes Announces Initiation Of Phase 1 Clinical Study Of Immuno-Oncology Drug Candidate ALKS 4230

Alkermes Announces Initiation Of Phase 1 Clinical Study Of Immuno-Oncology Drug Candidate ALKS 4230

Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell...

Alkermes To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting

Alkermes To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced that data and study design details from FORWARD-3 and FORWARD-4, two phase 3 studies of ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD), will be...

Alkermes Plc Reports First Quarter 2016 Financial Results

Alkermes Plc Reports First Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the first quarter of 2016.

Alkermes Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results

Alkermes Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results

Alkermes plc (NASDAQ: ALKS) today announced preliminary findings from a phase 1 clinical trial of ALKS 7119, an oral, novel small molecule that acts on multiple key receptor systems in the brain.

Alkermes To Host Conference Call To Discuss First Quarter 2016 Financial Results

Alkermes To Host Conference Call To Discuss First Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Stalking a Speculative Trade in Alkermes

The longer-term weekly chart is ugly, but optimistic in the near-term.

Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager

Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager

Shares of Acadia Pharmaceuticals popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Study On Extended-Release Naltrexone In Opioid-Dependent Patients Involved In Criminal Justice System Published In The New England Journal Of Medicine

Study On Extended-Release Naltrexone In Opioid-Dependent Patients Involved In Criminal Justice System Published In The New England Journal Of Medicine

Results from a study published this week in the New England Journal of Medicine ( NEJM) demonstrated the utility of extended-release naltrexone (VIVITROL ®) in individuals involved in the criminal justice system.

Alkermes To Present Data On Schizophrenia Portfolio At Upcoming Schizophrenia International Research Society Conference

Alkermes To Present Data On Schizophrenia Portfolio At Upcoming Schizophrenia International Research Society Conference

Alkermes plc (NASDAQ:ALKS) today announced that data from Alkermes' schizophrenia portfolio will be featured at the 5 th Biennial Schizophrenia International Research Society (SIRS) Conference to be held in Florence,...

Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016, at 8:30 a.

Weak On High Volume: Alkermes (ALKS)

Weak On High Volume: Alkermes (ALKS)

Trade-Ideas LLC identified Alkermes (ALKS) as a weak on high relative volume candidate

Insider Trading Alert - HAFC, ALKS And PRGO Traded By Insiders

Insider Trading Alert - HAFC, ALKS And PRGO Traded By Insiders

Stocks with insider trader activity include HAFC, ALKS and PRGO

Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock

Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Alkermes (ALKS) as a post-market leader candidate

Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 36th Annual Health Care Conference

Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 36th Annual Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 36 th Annual Health Care Conference on Tuesday, March 8, 2016, at 9:20 a.

Feb. 25 Premarket Briefing: 10 Things You Should Know

Feb. 25 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are edging higher heading into a major day for earnings, as investors await initial jobless claims data and durable goods order numbers.

Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2015 And Provides Financial Expectations For 2016

Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2015 And Provides Financial Expectations For 2016

Alkermes plc (NASDAQ: ALKS) today reported financial results for the twelve months ended Dec.

Alkermes Announces Positive Topline Results From Clinical Study Of Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia

Alkermes Announces Positive Topline Results From Clinical Study Of Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced positive topline data from a randomized, open-label, pharmacokinetic (PK) study evaluating a two-month dosing interval of ARISTADA ® (aripiprazole lauroxil)...

Alkermes (ALKS) Is Today's Dead Cat Bounce Stock

Alkermes (ALKS) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Alkermes (ALKS) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2015 Financial Results

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2015 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

5 Breakout Stocks to Trade for Big Gains

5 Breakout Stocks to Trade for Big Gains

These stocks looks ready to break out and trade higher from current levels.

Short Interest In Alkermes Drops 16%

Short Interest In Alkermes Drops 16%

The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 752,184 share decrease in total short interest for Alkermes plc , to 3,947,046, a decrease of 16.01% since 01/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Alkermes Announces Initiation Of Second Phase 3 Study Of ALKS 3831 For Schizophrenia

Alkermes Announces Initiation Of Second Phase 3 Study Of ALKS 3831 For Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced the initiation of ENLIGHTEN-2, the second of two core phase 3 studies for ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a...

Alkermes' Corporate Presentation To Be Webcast At Two Upcoming Conferences

Alkermes' Corporate Presentation To Be Webcast At Two Upcoming Conferences

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 18 th Annual BIO CEO & Investor Conference on Tuesday, Feb.

Alkermes Announces Initiation Of Phase 1 Clinical Study Of New CNS Drug Candidate ALKS 7119

Alkermes Announces Initiation Of Phase 1 Clinical Study Of New CNS Drug Candidate ALKS 7119

Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7119, an oral, investigational drug candidate being developed for the treatment of agitation in patients with Alzheimer's...

8 Things That Could Lift Biotech Stocks Out of Bear Market

8 Things That Could Lift Biotech Stocks Out of Bear Market

Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of Alkermes Plc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of Alkermes Plc

Levi & Korsinsky announces it has commenced an investigation of Alkermes plc (NASDAQGS: ALKS) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.